AnGes MG, Inc. - Product Pipeline Review - 2015

Published: Mar, 2015 | Pages: 43 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

AnGes MG, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'AnGes MG, Inc. - Product Pipeline Review - 2015', provides an overview of the AnGes MG, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AnGes MG, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of AnGes MG, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of AnGes MG, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the AnGes MG, Inc.'s pipeline products

Reasons To Buy

- Evaluate AnGes MG, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of AnGes MG, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the AnGes MG, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of AnGes MG, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of AnGes MG, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of AnGes MG, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
AnGes MG, Inc. Snapshot 5
AnGes MG, Inc. Overview 5
Key Information 5
Key Facts 5
AnGes MG, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
AnGes MG, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
AnGes MG, Inc. - Pipeline Products Glance 13
AnGes MG, Inc. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
AnGes MG, Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
AnGes MG, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
AnGes MG, Inc. - Drug Profiles 18
beperminogene perplasmid 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
velimogene aliplasmid 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
S-414114 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
AG-30/5C 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Antibody for Ebola Virus Viral Infections 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
AnGes MG, Inc. - Pipeline Analysis 30
AnGes MG, Inc. - Pipeline Products by Target 30
AnGes MG, Inc. - Pipeline Products by Route of Administration 31
AnGes MG, Inc. - Pipeline Products by Molecule Type 32
AnGes MG, Inc. - Pipeline Products by Mechanism of Action 33
AnGes MG, Inc. - Recent Pipeline Updates 34
AnGes MG, Inc. - Dormant Projects 37
AnGes MG, Inc. - Discontinued Pipeline Products 38
Discontinued Pipeline Product Profiles 38
S-414114 38
AnGes MG, Inc. - Company Statement 39
AnGes MG, Inc. - Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43

List of Tables
AnGes MG, Inc., Key Information 5
AnGes MG, Inc., Key Facts 5
AnGes MG, Inc. - Pipeline by Indication, 2015 8
AnGes MG, Inc. - Pipeline by Stage of Development, 2015 9
AnGes MG, Inc. - Monotherapy Products in Pipeline, 2015 10
AnGes MG, Inc. - Partnered Products in Pipeline, 2015 11
AnGes MG, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 12
AnGes MG, Inc. - Phase III, 2015 13
AnGes MG, Inc. - Phase II, 2015 14
AnGes MG, Inc. - Phase I, 2015 15
AnGes MG, Inc. - Preclinical, 2015 16
AnGes MG, Inc. - Discovery, 2015 17
AnGes MG, Inc. - Pipeline by Target, 2015 30
AnGes MG, Inc. - Pipeline by Route of Administration, 2015 31
AnGes MG, Inc. - Pipeline by Molecule Type, 2015 32
AnGes MG, Inc. - Pipeline Products by Mechanism of Action, 2015 33
AnGes MG, Inc. - Recent Pipeline Updates, 2015 34
AnGes MG, Inc. - Dormant Developmental Projects,2015 37
AnGes MG, Inc. - Discontinued Pipeline Products, 2015 38
AnGes MG, Inc., Other Locations 40
AnGes MG, Inc., Subsidiaries 41